Literature DB >> 23044494

Genetic variation in innate immunity and inflammation pathways associated with lung cancer risk.

Meredith S Shiels1, Eric A Engels, Jianxin Shi, Maria Teresa Landi, Demetrius Albanes, Nilanjan Chatterjee, Stephen J Chanock, Neil E Caporaso, Anil K Chaturvedi.   

Abstract

BACKGROUND: Pulmonary inflammation may contribute to lung cancer etiology. The authors conducted a broad evaluation of the association of single nucleotide polymorphisms (SNPs) in innate immunity and inflammation pathways with lung cancer risk and conducted comparisons with a lung cancer genome-wide association study (GWAS).
METHODS: In total, 378 patients with lung cancer (cases) and a group of 450 controls from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial were included. A proprietary oligonucleotide pool assay was used to genotype 1429 SNPs. Odds ratios and 95% confidence intervals were estimated for each SNP, and P values for trend (P(trend) ) were calculated. For statistically significant SNPs (P(trend) < .05), the results were replicated with genotyped or imputed SNPs in the GWAS, and P values were adjusted for multiple testing.
RESULTS: In the PLCO analysis, a significant association was observed between lung cancer and 81 SNPs located in 44 genes (P(trend) < .05). Of these 81 SNPS, there was evidence for confirmation in the GWAS for 10 SNPs. However, after adjusting for multiple comparisons, the only SNP that retained a significant association with lung cancer in the replication phase was reference SNP rs4648127 (nuclear factor of kappa light polypeptide gene enhancer of B-cells 1 [NFKB1]) (multiple testing-adjusted P(trend) = .02). The cytosine-thymine (CT)/TT genotype of NFKB1 was associated with reduced odds of lung cancer in the PLCO study (odds ratio, 0.56; 95% confidence interval, 0.37-0.86) and the in the GWAS (odds ratio, 0.79; 95% confidence interval, 0.69-0.90).
CONCLUSIONS: A significant association was observed between a variant in the NFKB1 gene and the risk of lung cancer. The current findings add to evidence implicating inflammation and immunity in lung cancer etiology. Published 2012 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23044494      PMCID: PMC3485420          DOI: 10.1002/cncr.27605

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  25 in total

1.  Polymorphisms in genes involved in the inflammatory response and interaction with NSAID use or smoking in relation to lung cancer risk in a prospective study.

Authors:  Ulla Vogel; Jane Christensen; Håkan Wallin; Søren Friis; Bjørn A Nexø; Ole Raaschou-Nielsen; Kim Overvad; Anne Tjønneland
Journal:  Mutat Res       Date:  2007-11-26       Impact factor: 2.433

2.  Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1.

Authors:  Christopher I Amos; Xifeng Wu; Peter Broderick; Ivan P Gorlov; Jian Gu; Timothy Eisen; Qiong Dong; Qing Zhang; Xiangjun Gu; Jayaram Vijayakrishnan; Kate Sullivan; Athena Matakidou; Yufei Wang; Gordon Mills; Kimberly Doheny; Ya-Yu Tsai; Wei Vivien Chen; Sanjay Shete; Margaret R Spitz; Richard S Houlston
Journal:  Nat Genet       Date:  2008-04-02       Impact factor: 38.330

3.  Genetic variation in tumor necrosis factor and the nuclear factor-kappaB canonical pathway and risk of non-Hodgkin's lymphoma.

Authors:  James R Cerhan; Wen Liu-Mares; Zachary S Fredericksen; Anne J Novak; Julie M Cunningham; Neil E Kay; Ahmet Dogan; Mark Liebow; Alice H Wang; Timothy G Call; Thomas M Habermann; Stephen M Ansell; Susan L Slager
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-11       Impact factor: 4.254

4.  A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25.

Authors:  Rayjean J Hung; James D McKay; Valerie Gaborieau; Paolo Boffetta; Mia Hashibe; David Zaridze; Anush Mukeria; Neonilia Szeszenia-Dabrowska; Jolanta Lissowska; Peter Rudnai; Eleonora Fabianova; Dana Mates; Vladimir Bencko; Lenka Foretova; Vladimir Janout; Chu Chen; Gary Goodman; John K Field; Triantafillos Liloglou; George Xinarianos; Adrian Cassidy; John McLaughlin; Geoffrey Liu; Steven Narod; Hans E Krokan; Frank Skorpen; Maiken Bratt Elvestad; Kristian Hveem; Lars Vatten; Jakob Linseisen; Françoise Clavel-Chapelon; Paolo Vineis; H Bas Bueno-de-Mesquita; Eiliv Lund; Carmen Martinez; Sheila Bingham; Torgny Rasmuson; Pierre Hainaut; Elio Riboli; Wolfgang Ahrens; Simone Benhamou; Pagona Lagiou; Dimitrios Trichopoulos; Ivana Holcátová; Franco Merletti; Kristina Kjaerheim; Antonio Agudo; Gary Macfarlane; Renato Talamini; Lorenzo Simonato; Ray Lowry; David I Conway; Ariana Znaor; Claire Healy; Diana Zelenika; Anne Boland; Marc Delepine; Mario Foglio; Doris Lechner; Fumihiko Matsuda; Helene Blanche; Ivo Gut; Simon Heath; Mark Lathrop; Paul Brennan
Journal:  Nature       Date:  2008-04-03       Impact factor: 49.962

5.  A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma.

Authors:  Maria Teresa Landi; Nilanjan Chatterjee; Kai Yu; Lynn R Goldin; Alisa M Goldstein; Melissa Rotunno; Lisa Mirabello; Kevin Jacobs; William Wheeler; Meredith Yeager; Andrew W Bergen; Qizhai Li; Dario Consonni; Angela C Pesatori; Sholom Wacholder; Michael Thun; Ryan Diver; Martin Oken; Jarmo Virtamo; Demetrius Albanes; Zhaoming Wang; Laurie Burdette; Kimberly F Doheny; Elizabeth W Pugh; Cathy Laurie; Paul Brennan; Rayjean Hung; Valerie Gaborieau; James D McKay; Mark Lathrop; John McLaughlin; Ying Wang; Ming-Sound Tsao; Margaret R Spitz; Yufei Wang; Hans Krokan; Lars Vatten; Frank Skorpen; Egil Arnesen; Simone Benhamou; Christine Bouchard; Andres Metspalu; Andres Metsapalu; Tonu Vooder; Mari Nelis; Kristian Välk; John K Field; Chu Chen; Gary Goodman; Patrick Sulem; Gudmar Thorleifsson; Thorunn Rafnar; Timothy Eisen; Wiebke Sauter; Albert Rosenberger; Heike Bickeböller; Angela Risch; Jenny Chang-Claude; H Erich Wichmann; Kari Stefansson; Richard Houlston; Christopher I Amos; Joseph F Fraumeni; Sharon A Savage; Pier Alberto Bertazzi; Margaret A Tucker; Stephen Chanock; Neil E Caporaso
Journal:  Am J Hum Genet       Date:  2009-10-15       Impact factor: 11.025

6.  Polymorphic variation in NFKB1 and other aspirin-related genes and risk of Hodgkin lymphoma.

Authors:  Ellen T Chang; Brenda M Birmann; Julie L Kasperzyk; David V Conti; Peter Kraft; Richard F Ambinder; Tongzhang Zheng; Nancy E Mueller
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-02-17       Impact factor: 4.254

7.  Lung cancer susceptibility locus at 5p15.33.

Authors:  James D McKay; Rayjean J Hung; Valerie Gaborieau; Paolo Boffetta; Amelie Chabrier; Graham Byrnes; David Zaridze; Anush Mukeria; Neonilia Szeszenia-Dabrowska; Jolanta Lissowska; Peter Rudnai; Eleonora Fabianova; Dana Mates; Vladimir Bencko; Lenka Foretova; Vladimir Janout; John McLaughlin; Frances Shepherd; Alexandre Montpetit; Steven Narod; Hans E Krokan; Frank Skorpen; Maiken Bratt Elvestad; Lars Vatten; Inger Njølstad; Tomas Axelsson; Chu Chen; Gary Goodman; Matt Barnett; Melissa M Loomis; Jan Lubiñski; Joanna Matyjasik; Marcin Lener; Dorota Oszutowska; John Field; Triantafillos Liloglou; George Xinarianos; Adrian Cassidy; Paolo Vineis; Francoise Clavel-Chapelon; Domenico Palli; Rosario Tumino; Vittorio Krogh; Salvatore Panico; Carlos A González; José Ramón Quirós; Carmen Martínez; Carmen Navarro; Eva Ardanaz; Nerea Larrañaga; Kay Tee Kham; Timothy Key; H Bas Bueno-de-Mesquita; Petra Hm Peeters; Antonia Trichopoulou; Jakob Linseisen; Heiner Boeing; Göran Hallmans; Kim Overvad; Anne Tjønneland; Merethe Kumle; Elio Riboli; Diana Zelenika; Anne Boland; Marc Delepine; Mario Foglio; Doris Lechner; Fumihiko Matsuda; Helene Blanche; Ivo Gut; Simon Heath; Mark Lathrop; Paul Brennan
Journal:  Nat Genet       Date:  2008-11-02       Impact factor: 38.330

8.  A specific interleukin-1B haplotype correlates with high levels of IL1B mRNA in the lung and increased risk of non-small cell lung cancer.

Authors:  Nina E Landvik; Kent Hart; Vidar Skaug; Lodve B Stangeland; Aage Haugen; Shanbeh Zienolddiny
Journal:  Carcinogenesis       Date:  2009-05-21       Impact factor: 4.944

9.  Chronic obstructive pulmonary disease and altered risk of lung cancer in a population-based case-control study.

Authors:  Jill Koshiol; Melissa Rotunno; Dario Consonni; Angela Cecilia Pesatori; Sara De Matteis; Alisa M Goldstein; Anil K Chaturvedi; Sholom Wacholder; Maria Teresa Landi; Jay H Lubin; Neil E Caporaso
Journal:  PLoS One       Date:  2009-10-08       Impact factor: 3.240

10.  A flexible and accurate genotype imputation method for the next generation of genome-wide association studies.

Authors:  Bryan N Howie; Peter Donnelly; Jonathan Marchini
Journal:  PLoS Genet       Date:  2009-06-19       Impact factor: 5.917

View more
  17 in total

1.  COPD-dependent effects of genetic variation in key inflammation pathway genes on lung cancer risk.

Authors:  Donovan Watza; Christine M Lusk; Gregory Dyson; Kristen S Purrington; Angela S Wenzlaff; Christine Neslund-Dudas; Ayman O Soubani; Shirish M Gadgeel; Ann G Schwartz
Journal:  Int J Cancer       Date:  2019-12-12       Impact factor: 7.396

2.  Germline Features Associated with Immune Infiltration in Solid Tumors.

Authors:  Sahar Shahamatdar; Meng Xiao He; Matthew A Reyna; Alexander Gusev; Saud H AlDubayan; Eliezer M Van Allen; Sohini Ramachandran
Journal:  Cell Rep       Date:  2020-03-03       Impact factor: 9.423

3.  NFKB1 -94ins/del ATTG polymorphism increases osteosarcoma risk in a Chinese Han population.

Authors:  Xiyi Li; Chenglin Zhang; Wei Qiao; Xuhui Zhou; Menghong Sun
Journal:  Int J Clin Exp Med       Date:  2015-01-15

4.  LATS2 inhibits the activity of NF-κ B signaling by disrupting the interaction between TAK1 and IKKβ.

Authors:  Feng Yao; Weizheng Zhou; Chenxi Zhong; Wentao Fang
Journal:  Tumour Biol       Date:  2015-05-07

5.  Causal Inference Analysis for Poorly Soluble Low Toxicity Particles, Lung Function, and Malignancy.

Authors:  Philip Harber
Journal:  Front Public Health       Date:  2022-07-05

6.  Circulating Inflammation Markers, Risk of Lung Cancer, and Utility for Risk Stratification.

Authors:  Meredith S Shiels; Hormuzd A Katki; Allan Hildesheim; Ruth M Pfeiffer; Eric A Engels; Marcus Williams; Troy J Kemp; Neil E Caporaso; Ligia A Pinto; Anil K Chaturvedi
Journal:  J Natl Cancer Inst       Date:  2015-07-28       Impact factor: 13.506

7.  A combined prognostic serum interleukin-8 and interleukin-6 classifier for stage 1 lung cancer in the prostate, lung, colorectal, and ovarian cancer screening trial.

Authors:  Bríd M Ryan; Sharon R Pine; Anil K Chaturvedi; Neil Caporaso; Curtis C Harris
Journal:  J Thorac Oncol       Date:  2014-10       Impact factor: 15.609

8.  Circulating inflammation markers and prospective risk for lung cancer.

Authors:  Meredith S Shiels; Ruth M Pfeiffer; Allan Hildesheim; Eric A Engels; Troy J Kemp; Ju-Hyun Park; Hormuzd A Katki; Jill Koshiol; Gloriana Shelton; Neil E Caporaso; Ligia A Pinto; Anil K Chaturvedi
Journal:  J Natl Cancer Inst       Date:  2013-11-18       Impact factor: 13.506

9.  Polymorphisms in NFKB1 and NFKBIA Genes Modulate the Risk of Developing Prostate Cancer among Han Chinese.

Authors:  Xiao Han; Jia-Jun Zhang; Nan Yao; Gang Wang; Juan Mei; Bo Li; Chao Li; Zi-An Wang
Journal:  Med Sci Monit       Date:  2015-06-12

10.  Combination of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio is a useful prognostic factor in advanced non-small cell lung cancer patients.

Authors:  Guannan Wu; Yanwen Yao; Cuiqing Bai; Junli Zeng; Donghong Shi; Xiaoling Gu; Xuefei Shi; Yong Song
Journal:  Thorac Cancer       Date:  2015-04-24       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.